在当前的研究中，我们从红海的沉积物样本中分离出了 Bacillus velezensis AG6 菌株，并通过传统的微生物学技术和系统发育的 16S rRNA 序列进行了鉴定。在筛选的 8 株菌株中，R6 菌株是最高产的异染色质聚糖 (EPS) 生产者，其产量为显著的 EPSF6 (5.79 g L-1)。通过 GPC 分析发现，EPSF6 分子的分子质量 (Mw) 为 2.7 × 104 g mol-1，数均质量 (Mn) 为 2.6 × 104 g mol-1。根据 FTIR 谱图显示，EPSF6 不含硫酸盐，但含有糖醛酸 (43.8%)。经过 HPLC 检测，EPSF6 分子的单糖成分为木糖、半乳糖和半乳糖醛酸，其摩尔比为 2.0 : 0.5 : 2.0。DPPH、H2O2 和ABTS 测试发现，在 100、300、500、1000 和 1500 μg mL-1 的浓度下，EPSF6 的抗氧化能力在 15、60、45 和 60 分钟后呈剂量-时间依赖性增加，且在 60 分钟后浓度从 100 μg mL-1 增加到 1500 μg mL-1，其抗氧化活性分别为 91.34 ± 1.1%、80.20 ± 1.4% 和 75.28 ± 1.1%。此外，EPSF6 对六种癌细胞系的增殖具有明显的抑制活性。我们还使用过氧化酶 (5-LOX) 和环氧合酶 (COX-2) 进行了抗炎测试。通过 MTP浊度法对 EPSF6 的 Gram 阳性菌、Gram 阴性菌和抗生物膜形成能力进行了检测。综上，本研究揭示了海洋源 Bacillus velezensis AG6 生产的次生代谢物的潜在药理学应用。随着全球范围内的更多研究和研究的进行，它对人类健康的预期影响将会增大。本文受英国皇家化学学会版权保护。

In the current study, Bacillus velezensis AG6 was isolated from sediment samples in the Red Sea, identified by traditional microbiological techniques and phylogenetic 16S rRNA sequences. Among eight isolates screened for exopolysaccharide (EPS) production, the R6 isolate was the highest producer with a significant fraction of EPS (EPSF6, 5.79 g L-1). The EPSF6 molecule was found to have a molecular weight (Mw) of 2.7 × 104 g mol-1 and a number average (Mn) of 2.6 × 104 g mol-1 when it was analyzed using GPC. The FTIR spectrum indicated no sulfate but uronic acid (43.8%). According to HPLC, the EPSF6 fraction's monosaccharides were xylose, galactose, and galacturonic acid in a molar ratio of 2.0 : 0.5 : 2.0. DPPH, H2O2, and ABTS tests assessed EPSF6's antioxidant capabilities at 100, 300, 500, 1000, and 1500 μg mL-1 for 15, 60, 45, and 60 minutes. The overall antioxidant activities were dose- and time-dependently increased, and improved by increasing concentrations from 100 to 1500 μg mL-1 after 60 minutes and found to be 91.34 ± 1.1%, 80.20 ± 1.4% and 75.28 ± 1.1% respectively. Next, EPSF6 displayed considerable inhibitory activity toward the proliferation of six cancerous cell lines. Anti-inflammatory tests were performed using lipoxygenase (5-LOX) and cyclooxygenase (COX-2). An MTP turbidity assay method was applied to show the ability of EPSF6 to inhibit Gram-positive bacteria, Gram-negative bacteria, and antibiofilm formation. Together, this study sheds light on the potential pharmacological applications of a secondary metabolite produced by marine Bacillus velezensis AG6. Its expected impact on human health will increase as more research and studies are conducted globally.This journal is © The Royal Society of Chemistry.